Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

Latest News

Cannabis for PTSD: MAPS’ MJP2 Trial Approved

Read More

How the Eudēmonia Summit Has Already Improved My Life

And why everyone should go to this conference in 2025. I walked into the Palm Beach County Convention Center on November 1st bursting with curiosity. The health and wellness conference I was there to take part in, called The Eudēmonia Summit, was the first of its kind. It was a name I hadn’t heard before…

Psilocybin Applications are Available in Colorado. What Exactly Does That Mean?

Colorado’s progressive step toward legalizing psilocybin, primarily for therapeutic purposes, has opened new doors for individuals seeking alternative mental health treatments. As of 2023, residents can apply for access to licensed psilocybin therapy sessions under regulated conditions, providing a safe environment for therapeutic and controlled use. This landmark move is a part of Proposition 122,…

Compass Pathways Streamlines Operations with Workforce Reduction and Shift in Research Focus

Compass Pathways (NASDAQ: CMPS) has announced plans to reduce its workforce by approximately 30% and halt early-stage research programs, as the company intensifies its focus on the late-stage development of its lead candidate, the COMP360 psilocybin therapy. The London-based mental health company revealed its restructuring strategy alongside its third-quarter financial results, which highlighted an increased…

Clinical Trial Design Has Never Been More Important for Psychedelics

The journey toward FDA approval for new drugs is fraught with challenges, but perhaps none is more critical than the proper structuring of clinical trials. This point was starkly illustrated by the recent decision of the U.S. Food and Drug Administration (FDA) to decline the approval of an MDMA-based treatment for post-traumatic stress disorder (PTSD)…